Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

February 28, 2018

Conditions
Non Small Cell Lung CancerBreast Cancer
Interventions
DRUG

YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

DRUG

YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

DRUG

YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

DRUG

PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

Trial Locations (12)

363000

Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou

710061

Shaaxi Provincial Tumor Hospital, Xi'an

Unknown

Cancer Institute and Hospital, CAMS, Beijing

Fujian cancer hospital, Fuzhou

Fujian Medical University Union Hospital, Fuzhou

Fuzhou General Hospital of Nanjing Military Command, Fuzhou

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Shanghai Changzheng Hospital, Shanghai

Shanghai Chest Hospital, Shanghai

Tongji Hospital, Tongji Medical College Huazhou University of Science & Technology, Wuhan

The First Affiliated Hospital of Xiamen University, Xiamen

Zhejiang cancer hospital, Zhejiang

All Listed Sponsors
lead

Xiamen Amoytop Biotech Co., Ltd.

INDUSTRY

NCT02005458 - Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy | Biotech Hunter | Biotech Hunter